US20120221040A1 - Absorbable Vascular Filter - Google Patents
Absorbable Vascular Filter Download PDFInfo
- Publication number
- US20120221040A1 US20120221040A1 US13/036,351 US201113036351A US2012221040A1 US 20120221040 A1 US20120221040 A1 US 20120221040A1 US 201113036351 A US201113036351 A US 201113036351A US 2012221040 A1 US2012221040 A1 US 2012221040A1
- Authority
- US
- United States
- Prior art keywords
- absorbable
- capture
- filter
- set forth
- vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002792 vascular Effects 0.000 title abstract description 27
- -1 polytrimethylene carbonate Polymers 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 5
- 239000000622 polydioxanone Substances 0.000 claims description 5
- 229920004937 Dexon® Polymers 0.000 claims description 4
- MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 claims description 3
- SCRCZNMJAVGGEI-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;oxepan-2-one Chemical compound O=C1COC(=O)CO1.O=C1CCCCCO1 SCRCZNMJAVGGEI-UHFFFAOYSA-N 0.000 claims description 3
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229910000531 Co alloy Inorganic materials 0.000 claims description 2
- 229910001257 Nb alloy Inorganic materials 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229910001260 Pt alloy Inorganic materials 0.000 claims description 2
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 claims description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 2
- 229950010732 poliglecaprone Drugs 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000010935 stainless steel Substances 0.000 claims 1
- 229910001220 stainless steel Inorganic materials 0.000 claims 1
- 210000001631 vena cava inferior Anatomy 0.000 abstract description 33
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract description 31
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract description 23
- 206010047249 Venous thrombosis Diseases 0.000 abstract description 23
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 description 11
- 238000011321 prophylaxis Methods 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 230000008733 trauma Effects 0.000 description 9
- 238000006065 biodegradation reaction Methods 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- 206010014522 Embolism venous Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000010100 anticoagulation Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 208000004043 venous thromboembolism Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000011882 arthroplasty Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000032767 Device breakage Diseases 0.000 description 1
- 208000036829 Device dislocation Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010048591 Post thrombotic syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003632 chemoprophylactic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012337 thromboprophylaxis Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/0105—Open ended, i.e. legs gathered only at one side
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2/011—Instruments for their placement or removal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
- A61F2002/016—Filters implantable into blood vessels made from wire-like elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0021—Angular shapes square
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0073—Quadric-shaped
- A61F2230/008—Quadric-shaped paraboloidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00017—Iron- or Fe-based alloys, e.g. stainless steel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00023—Titanium or titanium-based alloys, e.g. Ti-Ni alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00029—Cobalt-based alloys, e.g. Co-Cr alloys or Vitallium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00035—Other metals or alloys
- A61F2310/00071—Nickel or Ni-based alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00035—Other metals or alloys
- A61F2310/00095—Niobium or Nb-based alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00035—Other metals or alloys
- A61F2310/00131—Tantalum or Ta-based alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00035—Other metals or alloys
- A61F2310/00149—Platinum or Pt-based alloys
Definitions
- the present invention relates generally to a vascular filter and more particularly to an absorbable vascular filter deployed within a vessel for temporary filtering of body fluids.
- a preferred embodiment is the placement of such absorbable vascular filter within the inferior vena cava (IVC) for the prevention of pulmonary embolisms for a specific duration of time determined by the absorption properties of the filter.
- IVC inferior vena cava
- PE pulmonary embolism
- specific risk factors include hip and knee arthroplasty, abdominal, pelvic and extremity surgeries, pelvic and long bone fractures, prolonged immobility such as prolonged hospital stays and air travel, paralysis, advanced age, prior DVT, cancer, obesity, COPD, diabetes and CHF. Orthopedic surgeons are especially concerned since their patients carry a 40%-80% risk for DVT and PE following knee and hip surgeries in the absence of prophylactic treatment [10-12].
- AAOS American Academy of Orthopaedic Surgeons
- chemoprophylactic agents such as aspirin, low molecular weight heparin (LMWH), synthetic pentassaccharides, or warfarin, in addition to intra-operative and/or immediate postoperative mechanical prophylaxis [13].
- LMWH carries a 30% risk reduction in DVT and has been proven more effective than unfractionated heparin in high risk groups such as hip and knee arthroplasty [7].
- Warfarin started within 24 to 48 hours of initiating heparin with a goal of achieving international normalized ratio (INR) results between 2 and 3 as secondary thromboprophylaxis for 3 months reduces the risk of recurrent venous thromboembolism (VTE) by 90% as compared with placebo [15,16].
- VTE recurrent venous thromboembolism
- Mechanical prophylaxis consisting of pneumatic compression devices that repeatedly compress the legs with an air bladder, are also utilized in conjunction with anticoagulants to reduce the occurrence of PE.
- prophylaxis The duration of prophylaxis depends on the source of potential DVT. Current recommendations for prophylaxis consist of a minimum 7 days and up to 30 days for many orthopedic surgeries. Specifically for orthopedic trauma, DVT prophylaxis is continued until patient mobilization (32%), inpatient discharge (19%), 3 weeks postop (16%), 6 weeks postop (27%), and in rare circumstances greater than 6 weeks (7%) [17]. Studies indicate that hypercoaguability persists for at least one month after injury in 80% of trauma patients [18]. Regarding total knee and hip arthroplasty and cancer surgeries, 35 day prophylactic treatment is recommended [12,19]. Overall, prophylactic treatment for possible VTE is often warranted for up to 6 weeks following trauma or major surgery.
- Contraindications for chemoprophylaxis include active bleeding, hemorrhagic diathesis, hemorrhagic stroke, neurologic surgery, excessive trauma, hemothorax, pelvic or lower extremity fractures with intracranial bleeding, anticoagulation interruption, and recent DVT/PE patients undergoing surgery.
- IVC inferior vena cava
- Example vascular filters primarily for IVC placement are disclosed in U.S. Pat. No. 4,425,908; U.S. Pat. No. 4,817,600; U.S. Pat. No. 5,626,605; U.S. Pat. No. 6,146,404; U.S. Pat. No. 6,217,600 B1; U.S. Pat. No. 6,258,026 B1; U.S. Pat. No. 6,497,709 B1; U.S. Pat. No. 6,506,205 B2; U.S. Pat. No. 6,517,559 B1; U.S. Pat. No. 6,620,183 B2; U.S. Pat. App. Pub. No. 2003/0176888; U.S. Pat. App. Pub.
- IVC filter efficacy has been demonstrated in several class I and II evidence studies [22, 28-30]. Most of the earlier filters installed were expected to be permanent fixtures since endothelialization occurs within 7-10 days making most models impractical to remove without irreversible vascular damage leading to life threatening bleeding, dissection of the IVC, and thrombosis. Although these permanent filters have prevented PE, they have been shown to actually increase the risk of recurrent DVT over time.
- filter occlusion has been reported with a 6% to 30% occurrence, as well as filter migration (3% to 69%), venous insufficiency (5% to 59%), and post thrombotic syndrome (13% to 41%) [34-36].
- Complications from insertion including hematoma, infection, pneumothorax, vocal cord paralysis, stroke, air embolism, misplacement, tilting arteriovenous fistula, and inadvertent carotid artery puncture have an occurrence rate of 4%-11% [37].
- Temporary or retrievable IVC filters have been marketed more recently intended to be removed once the risk of PE subsides, and hence circumvent many of the deleterious complications of permanent filters.
- the retrievable filters feature flexible hooks, collapsing components, and unrestrained legs to ease retrieval. Unfortunately these same features have led to unwanted filter migration, fatigue failure, IVC penetration, fragment migration to hepatic veins and pulmonary arteries, filter tilt, and metallic emboli [38-43]. Since 2005, 921 adverse filter events have been reported to the FDA including 328 device migrations, 146 device detachments (metallic emboli), 70 perforations of the IVC, and 56 filter fractures [44].
- Some retrievable brands post alarming failure rates such as the Bard Recovery filter with 25% fracturing over 50 months which embolized end organs. 71% of the fractures embolized to the heart caused life threatening ventricular tachycardia, tamponade, and sudden death in some cases.
- An alternative retrievable model, Bard G2 resulted in 12% fractures over 24 months [45]. Such prevalence of device fractures is postulated to be directionally proportional to indwell time.
- the present invention comprises systems and methods for filtering fluids.
- Certain embodiments comprise a novel absorbable vascular filter that temporarily prevents pulmonary embolism by capturing and restraining emboli within a body vessel.
- the absorbable vascular filter according to certain aspects of the invention, possesses various advantages over all conventional vascular filters, including permanent, temporary, and optional IVC filters.
- the absorbable vascular filter disclosed herein is slowly biodegraded in a sequential manner within the vessel according to a planned schedule engineered by the choice of absorbable filter materials which prevents the requirement of filter removal.
- the absorbable vascular filter elements are manufactured from non-metallic synthetic polymers which do not adversely impact end organs upon carefully planned degradation as exhibited by conventional metal IVC filters that migrate and often become fractionated. Also due to the relative short indwell time (months) of the absorbable vascular filter, the paradoxical increase in DVT seen with conventional long-term IVC filters is likely circumvented.
- FIG. 1 a is a cut-away isometric view of one embodiment of the absorbable vascular filter that includes phased sequential biodegradation of the absorbable capture elements.
- FIG. 1 b features the capture elements of FIG. 1 a in detail.
- FIG. 1 c features the capture elements of FIG. 1 b at a later point in time wherein the proximal portion of the capture elements has been bioabsorbed/biodegraded.
- FIG. 1 d features the capture elements of FIG. 1 c at a later point in time wherein the proximal and middle sections of the capture elements have been bioabsorbed/biodegraded, leaving only the distal section.
- FIG. 1 e represents complete bioabsorption/biodegradation of the capture elements of FIG. 1 b at the most distant point in time.
- FIG. 2 a is a cross-sectional schematic of another embodiment of the absorbable vascular filter that also features phased sequential biodegradation of the absorbable capture elements.
- FIG. 2 b is an enlarged end-view of the absorbable capture elements of the absorbable filter depicted in FIG. 2 a.
- FIG. 2 c depicts the capture elements of FIG. 2 b at the time of filter installation in a vessel.
- FIG. 2 d depicts the capture elements of FIG. 2 c at a later point in time wherein the inner capture ring element has been bioabsorbed/biodegraded.
- FIG. 2 e depicts the capture elements of FIG. 2 d at a later point in time wherein a circumferential-mounted capture element has been bioabsorbed/biodegraded.
- FIG. 2 f depicts the capture elements of FIG. 2 e at a later point in time wherein two circumferential-mounted capture elements have been bioabsorbed/biodegraded.
- FIG. 2 g depicts the capture elements of FIG. 2 f at a later point in time wherein only one circumferential-mounted capture element remains following bioabsorption/biodegradation.
- FIG. 2 h depicts the capture elements of FIG. 2 b which have completely been bioabsorbed/biodegraded at the most distant point in time.
- FIG. 3 a is a cross-sectional schematic revealing a preferred method for installing the absorbable vascular filter using a catheter-based system with the filter in compressed mode.
- FIG. 3 b is a cross-sectional schematic detailing the deployment of the absorbable vascular filter using a catheter-based system with sliding outer sheath to deploy the filter in the fully expanded mode.
- FIG. 3 c is a cross-sectional schematic detailing the removal of the central stabilizing rod used to stabilize the absorbable vascular filter while removing the outer sheath of the catheter-based installation system.
- FIG. 3 d illustrates the operation of the absorbable vascular filter in the presence of an embolus in the vessel.
- FIG. 3 e represents the vessel following complete biodegradation/bioabsorption of the absorbable vascular filter.
- an absorbable vascular filter 1 consists of an outer, circumferential element 2 for supporting a plurality of absorbable filter capture elements ( 30 - 32 , 40 - 41 ).
- the capture elements are purposely designed to be biologically absorbed and/or degraded in a sequential manner to avoid simultaneous detachment of the entire filter causing an unexpected embolus.
- the sequential bioabsorption/biodegradation is illustrated in FIGS. 1 b - e where decomposition begins with the proximal capture elements 30 , progressing to the middle section capture elements 31 , and finally full bioabsorption/biodegradation as depicted in FIG. 1 e.
- Such engineered, sequential bioabsorption/biodegradation of the capture elements can be achieved with numerous synthetic materials.
- the goal is to select the absorbable filter materials to match a desired filter indwell time.
- a filter indwell time of 6 weeks would be suitable for an IVC filter to prevent PE following trauma or in conjunction with major surgeries.
- Plausible synthetic materials include:
- PDS Polydioxanone
- PDS II Ethicon, Somerville, N.J.
- PDS II size 4/0 and smaller maintains 60%, 40%, and 35% of its tensile strength at 2, 4, and 6 weeks respectively.
- PDS II size 3/0 and larger it retains 80%, 70%, and 60% of its tensile strength at 2, 4, and 6 weeks respectively.
- PDS II suture is fully absorbed in 183-238 days via hydrolysis making it a strong candidate for IVC filter applications. Basically absorption is minimal in the first 90 days and is essentially complete in 6 months.
- PDS has a low affinity for microorganisms and possesses minimal tissue reaction.
- Maxon Polytrimethylene carbonate (Maxon)—similar to PDS in absorption profile yet with slightly higher breaking strength. Maxon (Covidien, Mansfield, Mass.) maintains 81%, 59%, and 30% of its tensile strength at 2, 4, and 6 weeks respectively, and is fully hydrolyzed in 180-210 days.
- Polyglactin 910 (Vicryl)—braided multifilament coated with a copolymer of lactide and glycolide (polyglactin 370 ).
- Vicryl (Ethicon) size 6/0 and larger maintains 75%, 50%, and 25% of its tensile strength at 2, 3, and 4 weeks respectively and is fully absorbed in 56-70 days.
- Polyglycolic acid (Dexon)—similar to Polyglactin, made from polyglycolic acid and coated with polycaprolate. Dexon has similar tensile strength and absorption profile as Polyglactin.
- Poliglecaprone 25 Synthetic copolymer of glycolide and e-caprolactone.
- Monocryl Ethicon
- Monocryl maintains 50%-70% and 20%-40% of its tensile strength at 1 and 2 weeks respectively and is fully absorbed in 91-119 days.
- Polylacticoglycolic acid (PLGA) copolymer of monomers glycolic acid and lactic acid Polylacticoglycolic acid (PLGA) copolymer of monomers glycolic acid and lactic acid.
- PLGA Polylacticoglycolic acid
- Different forms and properties of PLGA can be fabricated by controlling the ratio of lactide to glycolide for polymerization
- PLGA degrades by hydrolysis with the absorption profile dependent on the monomer ratio; the higher content of glycolide, the faster degradation.
- the 50:50 copolymer exhibits the fastest degradation at 2 months. Since the polymer degrades in the body to produce lactic acid and glycolic acid, both being normal physiological substances, PLGA poses minimal systemic toxicity.
- the proximal capture elements 30 , 41 could be fabricated with PDS II size 4/0 (0.15 mm dia.), while the middle capture elements 31 , 40 fabricated with size 2/0 (0.3 mm dia.), and finally the distal capture elements 32 fabricated with size 2 (0.5 mm) PDS II suture.
- the vascular filter can be fabricated with absorbable or non-absorbable composite mesh.
- Candidates for a mesh capture system include polypropylene such as C-QUR (Atrium Medical Corp. Hudson N.H.), polypropylene encapsulated by polydioxanone as in PROCEED (Ethicon, Somerville, N.J.), polypropylene co-knitted with polyglycolic acid fibers as in Bard Sepramesh IP Composite (Davol, Inc., Warwick, R.I.), polyethylene terephathalate as in Parietiex Composite (Covidien, Mansfield, Mass.), and ePTFE used in DUALAMESH (W. Gore & Assoc. Inc., Flagstaff, Ariz.).
- an absorbable material such as described above or non-absorbable material can be utilized.
- a non-absorbable material would essentially serve as a permanent stent, lasting well beyond the life of the absorbable capture elements. This may be an important option in cases where the vessel needs assistance in maintaining patency.
- Both types of circumferential elements 2 would likely incorporate barbs 79 (refer FIG. 2 ) to maintain filter positioning upon deployment.
- Plausible non-absorbing materials for constructing the circumferential element include: Nitinol, Elgiloy, Phynox, 316 stainless steel, MP35N alloy, titanium alloy, platinum alloy, niobium alloys, cobalt alloys, and tantalum wire.
- FIGS. 2 a - 2 h illustrate another embodiment of the absorbable vascular filter wherein the absorbable capture elements 60 - 64 are mounted to a simple circumferential element 2 held against the vessel wall 70 with barbs 79 .
- the circumferential element 2 can be fabricated with absorbable or non-absorbable materials of the like described above.
- An enlarged cross-sectional view of the capture element assembly 65 is shown in FIG. 2 b . Notice that the sequential degradation of the capture elements is achieved by varying the diameter of the chosen absorbable material.
- the inner capture element 60 could be PDS II 4/0 (0.15 mm dia.) resulting in the fastest absorption as illustrated in FIG.
- a preferred installation of the absorbable vascular filter is via intravenous insertion with a catheter requiring only a local anesthetic as illustrated in FIGS. 3 a - e .
- the filter is collapsed and compressed within a delivery catheter comprised of an outer sheath 71 and internal applicator or stabilizer 73 on a central rod 72 as illustrated in FIG. 3 a .
- the delivery catheter is inserted into the patient's vasculature of convenient location, such as the femoral vein. Subsequently, the delivery catheter is fed through the vasculature until reaching the desired deployment location, typically just inferior to the renal veins.
- the compressed filter 50 is allowed to expand upon sliding the exterior sheath 71 in the distal direction while simultaneously holding the stabilizer rod 72 steady (refer FIG. 3 b ).
- the stabilizing rod 73 can also be retracted distally as depicted in FIG. 3 c . Consequently as a thrombosis event releases an embolus 80 , the embolus is captured by the absorbable vascular filter and is prevented from traveling to the heart and lungs thereby preventing a potentially fatal PE (refer FIG. 3 d ).
- the filter is biologically absorbed resulting in the absence of any foreign material in the vessel as depicted in FIG. 3 e.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
Abstract
An absorbable vascular filter is disclosed for deployment within a vessel for temporary filtering of body fluids. A preferred embodiment is the placement of such absorbable vascular filter within the inferior vena cava (IVC) to filter emboli for the prevention of pulmonary embolism for a limited duration in time. Once protection from PE is complete, the filter is sequentially biodegraded according to a planned schedule determined by the absorption properties of the filter components. Hence the temporary absorbable vascular filter obviates the long term complications of permanent IVC filters such as increased deep vein thrombosis, while also circumventing the removal requirement of metal retrievable IVC filters.
Description
- The present invention relates generally to a vascular filter and more particularly to an absorbable vascular filter deployed within a vessel for temporary filtering of body fluids. A preferred embodiment is the placement of such absorbable vascular filter within the inferior vena cava (IVC) for the prevention of pulmonary embolisms for a specific duration of time determined by the absorption properties of the filter.
- Between 100,000 to 300,000 Americans die annually from pulmonary embolism (PE)—more than breast cancer and AIDS combined—representing the 3rd leading cause of death in the US [1-5]. A similar incidence of PE is found in Europe with approximately 370,000 annual deaths [6]. Moreover, PE is the 3rd most common cause of death in trauma patients that survive the first 24 hours. An estimated 25% of all hospitalized patients have some form of deep vein thrombosis (DVT) which is often clinically unapparent unless PE develops [7]. On average, 33% of DVT will progress to symptomatic PE of which 10% will be fatal [6].
- The US Surgeon General has recognized this alarming statistic and in 2008 issued a formal Call to Action to Prevent DVT and PE[1]. Unfortunately, DVT/PE disproportionately affects the elderly, in part due to prolonged periods of inactivity following medical treatment. The incidence is relatively low under the age of 50 ( 1/100,000), then accelerates exponentially reaching 1000/100,000 by the age of 85[8]. Consequently the US Surgeon General has proclaimed that the growth in number of DVT/PE cases with an aging US population may outpace the population growth in the absence of better prevention [1].
- Risk factors for PE arising from DVT follow Virchow's Triad [9]: (i) endothelial injury, (ii) hypercoaguability, and (iii) hemodynamic changes (stasis or turbulence). Hence specific risk factors include hip and knee arthroplasty, abdominal, pelvic and extremity surgeries, pelvic and long bone fractures, prolonged immobility such as prolonged hospital stays and air travel, paralysis, advanced age, prior DVT, cancer, obesity, COPD, diabetes and CHF. Orthopedic surgeons are especially concerned since their patients carry a 40%-80% risk for DVT and PE following knee and hip surgeries in the absence of prophylactic treatment [10-12].
- The American Academy of Orthopaedic Surgeons (AAOS) has issued guidelines for PE prophylaxis. Basically, patients at standard risk should be considered for chemoprophylactic agents such as aspirin, low molecular weight heparin (LMWH), synthetic pentassaccharides, or warfarin, in addition to intra-operative and/or immediate postoperative mechanical prophylaxis [13].
- Aspirin has a 29% relative risk reduction in symptomatic DVT and a 58% relative risk reduction in fatal PE [14]. LMWH carries a 30% risk reduction in DVT and has been proven more effective than unfractionated heparin in high risk groups such as hip and knee arthroplasty [7]. Warfarin started within 24 to 48 hours of initiating heparin with a goal of achieving international normalized ratio (INR) results between 2 and 3 as secondary thromboprophylaxis for 3 months reduces the risk of recurrent venous thromboembolism (VTE) by 90% as compared with placebo [15,16]. Mechanical prophylaxis, consisting of pneumatic compression devices that repeatedly compress the legs with an air bladder, are also utilized in conjunction with anticoagulants to reduce the occurrence of PE.
- The duration of prophylaxis depends on the source of potential DVT. Current recommendations for prophylaxis consist of a minimum 7 days and up to 30 days for many orthopedic surgeries. Specifically for orthopedic trauma, DVT prophylaxis is continued until patient mobilization (32%), inpatient discharge (19%), 3 weeks postop (16%), 6 weeks postop (27%), and in rare circumstances greater than 6 weeks (7%) [17]. Studies indicate that hypercoaguability persists for at least one month after injury in 80% of trauma patients [18]. Regarding total knee and hip arthroplasty and cancer surgeries, 35 day prophylactic treatment is recommended [12,19]. Overall, prophylactic treatment for possible VTE is often warranted for up to 6 weeks following trauma or major surgery.
- Contraindications for chemoprophylaxis include active bleeding, hemorrhagic diathesis, hemorrhagic stroke, neurologic surgery, excessive trauma, hemothorax, pelvic or lower extremity fractures with intracranial bleeding, anticoagulation interruption, and recent DVT/PE patients undergoing surgery.
- For patients who are contraindicated for the above-mentioned anti-coagulation prophylaxis, or where anti-coagulation therapy has failed, the AAOS, American College of Physicians, and the British Committee of Standards in Haematology all recommend the use of inferior vena cava (IVC) filters [13, 20, 21]. These intravascular metal filters are deployed via catheter into the IVC to essentially catch emboli arising from DVT before reaching the lungs resulting in PE. Furthermore, the British Committee of Standards in Hematology recommends IVC filter placement in pregnant patients who have contraindications to anticoagulation and develop extensive VTE shortly before delivery (within 2 weeks).
- The Eastern Association for Surgery of Trauma further recommends prophylactic IVC filters placed in trauma patients who are at increased risk of bleeding and prolonged immobilization [22]. Such prophylactic recommendation follows studies that demonstrate a low rate of PE in patients with severe polytrauma who underwent IVC placement [23-25]. In fact the fastest growing indication of overall IVC filter usage, from 49,000 in 1999 to 167,000 in 2007 with a projected 259,000 units for 2012, is the prophylactic market utilizing retrievable IVC filters [26, 27].
- Example vascular filters primarily for IVC placement are disclosed in U.S. Pat. No. 4,425,908; U.S. Pat. No. 4,817,600; U.S. Pat. No. 5,626,605; U.S. Pat. No. 6,146,404; U.S. Pat. No. 6,217,600 B1; U.S. Pat. No. 6,258,026 B1; U.S. Pat. No. 6,497,709 B1; U.S. Pat. No. 6,506,205 B2; U.S. Pat. No. 6,517,559 B1; U.S. Pat. No. 6,620,183 B2; U.S. Pat. App. Pub. No. 2003/0176888; U.S. Pat. App. Pub. No. 2004/0193209; U.S. Pat. App. Pub. No. 2005/0267512; U.S. Pat. App. Pub. No. 2005/0267515; U.S. Pat. App. Pub. No. 2006/0206138 A1; U.S. Pat. App. Pub. No. 2007/0112372 A1; U.S. Pat. App. Pub. No. 2008/0027481 A1; U.S. Pat. App. Pub. No. 2009/0192543 A1; U.S. Pat. App. Pub. No. 2009/0299403 A1; U.S. Pat. App. Pub. No. 2010/0016881 A1; U.S. Pat. App. Pub. No. 2010/0042135 A1; and U.S. Pat. App. Pub. No. 2010/0174310 A1.
- IVC filter efficacy has been demonstrated in several class I and II evidence studies [22, 28-30]. Most of the earlier filters installed were expected to be permanent fixtures since endothelialization occurs within 7-10 days making most models impractical to remove without irreversible vascular damage leading to life threatening bleeding, dissection of the IVC, and thrombosis. Although these permanent filters have prevented PE, they have been shown to actually increase the risk of recurrent DVT over time.
- Specifically, a Cochrane review [31] on the use of IVC filters for the prevention of PE cites a level I randomized prospective clinical trial by Decousus et al. [32] wherein the incidence of DVT with the IVC filter cohort increased almost 2-fold: (i) 21% incidence of recurrent DVT in the filter cohort vs. 12% in the non-filter LMWH cohort at 2 years (p=0.02), and (ii) 36% incidence of recurrent DVT in the filter cohort vs. 15% in the non-filter group at 8 years (p=0.042) [33]. However, the filters did reduce the occurrence of PE; the filter cohort experiencing only 1% PE vs. the non-filter cohort posting 5% PE in the first 12 days (p=0.03). No statistically significant difference in mortality rate was seen in any time frame investigated. Apparently the initial benefit of reduced PE with permanent IVC filters is offset by an increase in DVT, without any difference in mortality.
- In addition to increased incidence of DVT for prolonged IVC filter deployment, filter occlusion has been reported with a 6% to 30% occurrence, as well as filter migration (3% to 69%), venous insufficiency (5% to 59%), and post thrombotic syndrome (13% to 41%) [34-36]. Complications from insertion including hematoma, infection, pneumothorax, vocal cord paralysis, stroke, air embolism, misplacement, tilting arteriovenous fistula, and inadvertent carotid artery puncture have an occurrence rate of 4%-11% [37].
- Temporary or retrievable IVC filters have been marketed more recently intended to be removed once the risk of PE subsides, and hence circumvent many of the deleterious complications of permanent filters. The retrievable filters feature flexible hooks, collapsing components, and unrestrained legs to ease retrieval. Unfortunately these same features have led to unwanted filter migration, fatigue failure, IVC penetration, fragment migration to hepatic veins and pulmonary arteries, filter tilt, and metallic emboli [38-43]. Since 2005, 921 adverse filter events have been reported to the FDA including 328 device migrations, 146 device detachments (metallic emboli), 70 perforations of the IVC, and 56 filter fractures [44]. Some retrievable brands post alarming failure rates such as the Bard Recovery filter with 25% fracturing over 50 months which embolized end organs. 71% of the fractures embolized to the heart caused life threatening ventricular tachycardia, tamponade, and sudden death in some cases. An alternative retrievable model, Bard G2, resulted in 12% fractures over 24 months [45]. Such prevalence of device fractures is postulated to be directionally proportional to indwell time.
- These failures and others prompted the FDA in August 2010 to issue a formal communication stating that “FDA recommends that implanting physicians and clinicians responsible for the ongoing care of patients with retrievable IVC filters consider removing the filter as soon as protection from PE is not longer needed” [44]. Even though these types of retrievable filters are intended to be removed in months time, several studies indicate that approximately 70%-81% of patients with retrievable IVC filters fail to return to the hospital for filter removal, thereby exposing hundreds of thousands of patients to the life-threatening adverse events of prolonged retrievable IVC filter placement [41, 44, 46-48]. These patients are either lost to follow-up, or refuse to have the filters removed in the absence of complications.
- The present invention comprises systems and methods for filtering fluids. Certain embodiments comprise a novel absorbable vascular filter that temporarily prevents pulmonary embolism by capturing and restraining emboli within a body vessel. The absorbable vascular filter, according to certain aspects of the invention, possesses various advantages over all conventional vascular filters, including permanent, temporary, and optional IVC filters. Most importantly, the absorbable vascular filter disclosed herein is slowly biodegraded in a sequential manner within the vessel according to a planned schedule engineered by the choice of absorbable filter materials which prevents the requirement of filter removal. Moreover, the absorbable vascular filter elements are manufactured from non-metallic synthetic polymers which do not adversely impact end organs upon carefully planned degradation as exhibited by conventional metal IVC filters that migrate and often become fractionated. Also due to the relative short indwell time (months) of the absorbable vascular filter, the paradoxical increase in DVT seen with conventional long-term IVC filters is likely circumvented.
-
FIG. 1 a is a cut-away isometric view of one embodiment of the absorbable vascular filter that includes phased sequential biodegradation of the absorbable capture elements. -
FIG. 1 b features the capture elements ofFIG. 1 a in detail. -
FIG. 1 c features the capture elements ofFIG. 1 b at a later point in time wherein the proximal portion of the capture elements has been bioabsorbed/biodegraded. -
FIG. 1 d features the capture elements ofFIG. 1 c at a later point in time wherein the proximal and middle sections of the capture elements have been bioabsorbed/biodegraded, leaving only the distal section. -
FIG. 1 e represents complete bioabsorption/biodegradation of the capture elements ofFIG. 1 b at the most distant point in time. -
FIG. 2 a is a cross-sectional schematic of another embodiment of the absorbable vascular filter that also features phased sequential biodegradation of the absorbable capture elements. -
FIG. 2 b is an enlarged end-view of the absorbable capture elements of the absorbable filter depicted inFIG. 2 a. -
FIG. 2 c depicts the capture elements ofFIG. 2 b at the time of filter installation in a vessel. -
FIG. 2 d depicts the capture elements ofFIG. 2 c at a later point in time wherein the inner capture ring element has been bioabsorbed/biodegraded. -
FIG. 2 e depicts the capture elements ofFIG. 2 d at a later point in time wherein a circumferential-mounted capture element has been bioabsorbed/biodegraded. -
FIG. 2 f depicts the capture elements ofFIG. 2 e at a later point in time wherein two circumferential-mounted capture elements have been bioabsorbed/biodegraded. -
FIG. 2 g depicts the capture elements ofFIG. 2 f at a later point in time wherein only one circumferential-mounted capture element remains following bioabsorption/biodegradation. -
FIG. 2 h depicts the capture elements ofFIG. 2 b which have completely been bioabsorbed/biodegraded at the most distant point in time. -
FIG. 3 a is a cross-sectional schematic revealing a preferred method for installing the absorbable vascular filter using a catheter-based system with the filter in compressed mode. -
FIG. 3 b is a cross-sectional schematic detailing the deployment of the absorbable vascular filter using a catheter-based system with sliding outer sheath to deploy the filter in the fully expanded mode. -
FIG. 3 c is a cross-sectional schematic detailing the removal of the central stabilizing rod used to stabilize the absorbable vascular filter while removing the outer sheath of the catheter-based installation system. -
FIG. 3 d illustrates the operation of the absorbable vascular filter in the presence of an embolus in the vessel. -
FIG. 3 e represents the vessel following complete biodegradation/bioabsorption of the absorbable vascular filter. - Embodiments of the present invention will now be described in detail with reference to the drawings, which are provided as illustrative examples so as to enable those skilled in the art to practice the invention. Notably, the figures and examples below are not meant to limit the scope of the present invention to a single embodiment, but other embodiments are possible by way of interchange of some or all of the described or illustrated elements. Wherever convenient, the same reference numbers will be used throughout the drawings to refer to same or like parts. Where certain elements of these embodiments can be partially or fully implemented using known components, only those portions of such known components that are necessary for an understanding of the present invention will be described, and detailed descriptions of other portions of such known components will be omitted so as not to obscure the invention. In the present specification, an embodiment showing a singular component should not be considered limiting; rather, the invention is intended to encompass other embodiments including a plurality of the same component, and vice-versa, unless explicitly stated otherwise herein. Moreover, applicants do not intend for any term in the specification or claims to be ascribed an uncommon or special meaning unless explicitly set forth as such. Further, the present invention encompasses present and future known equivalents to the components referred to herein by way of illustration.
- Referring to the embodiment depicted in
FIGS. 1 a-e, an absorbable vascular filter 1 consists of an outer, circumferential element 2 for supporting a plurality of absorbable filter capture elements (30-32, 40-41). The capture elements are purposely designed to be biologically absorbed and/or degraded in a sequential manner to avoid simultaneous detachment of the entire filter causing an unexpected embolus. The sequential bioabsorption/biodegradation is illustrated inFIGS. 1 b-e where decomposition begins with theproximal capture elements 30, progressing to the middle section capture elements 31, and finally full bioabsorption/biodegradation as depicted inFIG. 1 e. - Such engineered, sequential bioabsorption/biodegradation of the capture elements can be achieved with numerous synthetic materials. The goal is to select the absorbable filter materials to match a desired filter indwell time. Per the prior background section, a filter indwell time of 6 weeks would be suitable for an IVC filter to prevent PE following trauma or in conjunction with major surgeries. Plausible synthetic materials include:
- Polydioxanone (PDO, PDS)—colorless, crystalline, biodegradable synthetic polymer of multiple repeating ether-ester units. In suture form, PDS II (Ethicon, Somerville, N.J.) size 4/0 and smaller maintains 60%, 40%, and 35% of its tensile strength at 2, 4, and 6 weeks respectively. For PDS II size 3/0 and larger, it retains 80%, 70%, and 60% of its tensile strength at 2, 4, and 6 weeks respectively. In addition to providing wound support for 6 weeks, PDS II suture is fully absorbed in 183-238 days via hydrolysis making it a strong candidate for IVC filter applications. Basically absorption is minimal in the first 90 days and is essentially complete in 6 months. Finally, PDS has a low affinity for microorganisms and possesses minimal tissue reaction.
- Polytrimethylene carbonate (Maxon)—similar to PDS in absorption profile yet with slightly higher breaking strength. Maxon (Covidien, Mansfield, Mass.) maintains 81%, 59%, and 30% of its tensile strength at 2, 4, and 6 weeks respectively, and is fully hydrolyzed in 180-210 days.
- Polyglactin 910 (Vicryl)—braided multifilament coated with a copolymer of lactide and glycolide (polyglactin 370). In suture form, Vicryl (Ethicon) size 6/0 and larger maintains 75%, 50%, and 25% of its tensile strength at 2, 3, and 4 weeks respectively and is fully absorbed in 56-70 days.
- Polyglycolic acid (Dexon)—similar to Polyglactin, made from polyglycolic acid and coated with polycaprolate. Dexon has similar tensile strength and absorption profile as Polyglactin.
- Poliglecaprone 25 (Monocryl)—synthetic copolymer of glycolide and e-caprolactone. Monocryl (Ethicon) maintains 50%-70% and 20%-40% of its tensile strength at 1 and 2 weeks respectively and is fully absorbed in 91-119 days.
- Polylacticoglycolic acid (PLGA) copolymer of monomers glycolic acid and lactic acid. Different forms and properties of PLGA can be fabricated by controlling the ratio of lactide to glycolide for polymerization Like the other synthetic absorbable materials, PLGA degrades by hydrolysis with the absorption profile dependent on the monomer ratio; the higher content of glycolide, the faster degradation. However, the 50:50 copolymer exhibits the fastest degradation at 2 months. Since the polymer degrades in the body to produce lactic acid and glycolic acid, both being normal physiological substances, PLGA poses minimal systemic toxicity.
- As a specific example of engineering capture elements to sequentially degrade following the period of PE protection, the
proximal capture elements 30, 41 could be fabricated with PDS II size 4/0 (0.15 mm dia.), while the middle capture elements 31, 40 fabricated with size 2/0 (0.3 mm dia.), and finally the distal capture elements 32 fabricated with size 2 (0.5 mm) PDS II suture. - As an alternative to assembling a plurality of capture elements, the vascular filter can be fabricated with absorbable or non-absorbable composite mesh. Candidates for a mesh capture system include polypropylene such as C-QUR (Atrium Medical Corp. Hudson N.H.), polypropylene encapsulated by polydioxanone as in PROCEED (Ethicon, Somerville, N.J.), polypropylene co-knitted with polyglycolic acid fibers as in Bard Sepramesh IP Composite (Davol, Inc., Warwick, R.I.), polyethylene terephathalate as in Parietiex Composite (Covidien, Mansfield, Mass.), and ePTFE used in DUALAMESH (W. Gore & Assoc. Inc., Flagstaff, Ariz.).
- Regarding the circumferential element 2 in
FIGS. 1 and 2 that serves to support the capture elements of the absorbable vascular filter and maintain filter positioning within the vessel upon expansion, either an absorbable material such as described above or non-absorbable material can be utilized. A non-absorbable material would essentially serve as a permanent stent, lasting well beyond the life of the absorbable capture elements. This may be an important option in cases where the vessel needs assistance in maintaining patency. Both types of circumferential elements 2 would likely incorporate barbs 79 (referFIG. 2 ) to maintain filter positioning upon deployment. Plausible non-absorbing materials for constructing the circumferential element include: Nitinol, Elgiloy, Phynox, 316 stainless steel, MP35N alloy, titanium alloy, platinum alloy, niobium alloys, cobalt alloys, and tantalum wire. -
FIGS. 2 a-2 h illustrate another embodiment of the absorbable vascular filter wherein the absorbable capture elements 60-64 are mounted to a simple circumferential element 2 held against the vessel wall 70 with barbs 79. Here again the circumferential element 2 can be fabricated with absorbable or non-absorbable materials of the like described above. An enlarged cross-sectional view of thecapture element assembly 65 is shown inFIG. 2 b. Notice that the sequential degradation of the capture elements is achieved by varying the diameter of the chosen absorbable material. For example, the inner capture element 60 could be PDS II 4/0 (0.15 mm dia.) resulting in the fastest absorption as illustrated inFIG. 2 d at time t1, followed by capture element 61 degradation being PDS II 3/0 (0.20 mm dia.) at time t2 inFIG. 2 e, followed by capture element 62 degradation being PDS II 2/0 (0.30 mm dia.) at time t3 inFIG. 2 f, followed by capture element 63 degradation being PDS II 0 (0.35 mm dia.) at time t4 inFIG. 2 g, and finally the degradation of the last capture element 64 constructed of PDS II 1 (0.40 mm dia.) at time t5 inFIG. 2 h. Overall, a gradual progression of degradation is designed purposely following a prophylactic window of 6 weeks for trauma and major surgery applications. - A preferred installation of the absorbable vascular filter is via intravenous insertion with a catheter requiring only a local anesthetic as illustrated in
FIGS. 3 a-e. Here the filter is collapsed and compressed within a delivery catheter comprised of an outer sheath 71 and internal applicator or stabilizer 73 on a central rod 72 as illustrated inFIG. 3 a. For IVC filter deployment, the delivery catheter is inserted into the patient's vasculature of convenient location, such as the femoral vein. Subsequently, the delivery catheter is fed through the vasculature until reaching the desired deployment location, typically just inferior to the renal veins. Next the compressed filter 50 is allowed to expand upon sliding the exterior sheath 71 in the distal direction while simultaneously holding the stabilizer rod 72 steady (referFIG. 3 b). Once the exterior sheath 71 is withdrawn distally away from the filter, the stabilizing rod 73 can also be retracted distally as depicted inFIG. 3 c. Consequently as a thrombosis event releases an embolus 80, the embolus is captured by the absorbable vascular filter and is prevented from traveling to the heart and lungs thereby preventing a potentially fatal PE (referFIG. 3 d). Following the desired prophylactic time window for filter utilization (approximately 6 weeks in many applications), the filter is biologically absorbed resulting in the absence of any foreign material in the vessel as depicted inFIG. 3 e. - Although the present invention has been described with reference to specific exemplary embodiments, it will be evident to one of ordinary skill in the art that various modifications and changes may be made to these embodiments without departing from the broader spirit and scope of the invention. Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense.
Claims (18)
1. An absorbable filter comprising:
a circumferential element attached to a vessel; and
a plurality of absorbable capture elements affixed to the circumferential element for capturing unwanted substances flowing in a vessel for a limited period of time.
2. A device as set forth in claim 1 , wherein more than one absorbable capture element has both ends attached to the circumferential element to form a loop, such that collectively the loops form a capture basket.
3. A device as set forth in claim 1 , wherein more than one absorbable capture element has both ends attached to the circumferential element to form a loop, and at least one capture element serves to integrate the loops to form a capture basket.
4. A device as set forth in claim 1 , wherein more than one absorbable capture element has both ends attached to the circumferential element to form a loop that does not extend to the radial center of the circumferential element, and at least one capture element serves to integrate the loops to form a capture basket.
5. A device as set forth in claim 1 , wherein a subset of the absorbable capture elements are chosen to sequentially degrade in time to avoid simultaneous bulk release of capture elements in the vessel over time.
6. A device as set forth in claim 1 , wherein the capture members are fabricated from absorbable materials including, but not limited to, polydioxanone, polytrimethylene carbonate, polyglactin, polyglycolic acid, poliglecaprone, polyglytone, and polylacticoglycolic acid.
7. A device as set forth in claim 1 , wherein the capture members are absorbable sutures.
8. A device as set forth in claim 7 , wherein the capture members are constructed from absorbable sutures including, but not limited to, Vicryl, Monocryl, PDS, PDS II, Dexon, Dexon II, Maxon, PLGA, Surgical Gut, Ethibond, Panacryl, Caprosyn,
9. A device as set forth in claim 1 , wherein the circumferential element is non-absorbable.
10. A device as set forth in claim 1 , wherein the circumferential element is absorbable.
11. A device as set forth in claim 1 , wherein the circumferential element is fabricated of materials including, but not limited to, Nitinol, Elgiloy, Phynox, stainless steel, MP35N alloy, titanium alloy, platinum alloy, niobium alloy, cobalt alloy, or tantalum wire.
12. A device as set forth in claim 1 , wherein the circumferential element is fabricated of absorbable materials including, but not limited to, polydioxanone, polytrimethylene carbonate, polyglactin, polyglycolic acid, poliglecaprone, polyglytone, or polylacticoglycolic acid.
13. A device as set forth in claim 1 , wherein the circumferential element comprises an anchor element or barb for attachment to a vessel.
14. An absorbable filter comprising:
a circumferential element attached to a vessel; and
a capture basket affixed to the circumferential element for capturing unwanted substances flowing in a vessel for a limited period of time.
15. A device as set forth in claim 14 , wherein the capture basket is a mesh.
16. A device as set forth in claim 15 , wherein the capture basket is fabricated from materials including, but not limited to, polypropylene, polypropylene encapsulated in polydioxanone, polypropylene co-knitted with polyglycolic acid fibers, polyethylene terephathalate, and ePTFE.
17. A device as set forth in claim 15 , wherein the capture basket is fabricated from materials including, but not limited to, C-QUR, PROCEED, Bard Sepramesh IP Composite, Parietiex Composite and DUALAMESH.
18. A method for delivering a filter as claimed in 1 and 14 with a delivery catheter wherein the delivery comprises:
inserting the filter, in compressed form, within a delivery catheter to a desired position within a vessel; and
deploying the filter in expanded form at the desired position within a vessel; and
subsequently removing delivery catheter from the vessel.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/036,351 US20120221040A1 (en) | 2011-02-28 | 2011-02-28 | Absorbable Vascular Filter |
PCT/US2012/026398 WO2012118696A1 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
EP12752614.3A EP2680784B1 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
CA2828480A CA2828480C (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
CN201280010783.0A CN103458826B (en) | 2011-02-28 | 2012-02-23 | absorbable vascular filter |
US13/403,790 US10531942B2 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
ES12752614T ES2887230T3 (en) | 2011-02-28 | 2012-02-23 | absorbable vascular filter |
KR1020137025601A KR101903952B1 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
AU2012223607A AU2012223607A1 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
BR112013021716-2A BR112013021716B1 (en) | 2011-02-28 | 2012-02-23 | absorbable filter |
JP2013556739A JP6415053B2 (en) | 2011-02-28 | 2012-02-23 | Absorptive vascular filter |
AU2016200592A AU2016200592B2 (en) | 2011-02-28 | 2016-02-01 | Absorbable vascular filter |
US15/174,973 US10383718B2 (en) | 2011-02-28 | 2016-06-06 | Absorbable vascular filter |
JP2017076169A JP6996861B2 (en) | 2011-02-28 | 2017-04-06 | Absorbable vessel filter |
US15/586,123 US20170231743A1 (en) | 2011-02-28 | 2017-05-03 | Absorbable vascular filter |
US16/659,536 US20200113667A1 (en) | 2011-02-28 | 2019-10-21 | Absorbable vascular filter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/036,351 US20120221040A1 (en) | 2011-02-28 | 2011-02-28 | Absorbable Vascular Filter |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/096,049 Continuation-In-Part US20120277787A1 (en) | 2011-02-28 | 2011-04-28 | Vascular Filter Stent |
US13/403,790 Continuation-In-Part US10531942B2 (en) | 2011-02-28 | 2012-02-23 | Absorbable vascular filter |
US15/174,973 Continuation US10383718B2 (en) | 2011-02-28 | 2016-06-06 | Absorbable vascular filter |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120221040A1 true US20120221040A1 (en) | 2012-08-30 |
Family
ID=46719507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/036,351 Abandoned US20120221040A1 (en) | 2011-02-28 | 2011-02-28 | Absorbable Vascular Filter |
US15/174,973 Active 2031-05-23 US10383718B2 (en) | 2011-02-28 | 2016-06-06 | Absorbable vascular filter |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/174,973 Active 2031-05-23 US10383718B2 (en) | 2011-02-28 | 2016-06-06 | Absorbable vascular filter |
Country Status (1)
Country | Link |
---|---|
US (2) | US20120221040A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016010452A1 (en) | 2014-07-14 | 2016-01-21 | Ic "Sovremennie Tehnologii", Ltd | Multipurpose vascular implant |
US20170105830A1 (en) * | 2015-10-19 | 2017-04-20 | Cook Medical Technologies Llc | Biodegradable vascular filter |
CN107028680A (en) * | 2017-06-06 | 2017-08-11 | 贾伟 | A kind of vena cava filter |
EP3272311A1 (en) | 2016-07-21 | 2018-01-24 | Cook Medical Technologies LLC | Implantable medical device and method of manufacture |
US10076398B2 (en) | 2012-12-27 | 2018-09-18 | Cook Medical Technologies Llc | Biodegradable filter |
US10117736B2 (en) | 2014-08-06 | 2018-11-06 | Cook Medical Technologies Llc | Low radial force filter |
US10123863B2 (en) | 2014-03-28 | 2018-11-13 | Cook Medical Technologies Llc | Mechanism for applying high radial force in less-elastic medical devices |
US10123864B2 (en) | 2014-06-30 | 2018-11-13 | Cook Medical Technologies Llc | Vascular filter and anchoring arrangement thereof |
CN109199631A (en) * | 2018-09-26 | 2019-01-15 | 李雷 | Inferior caval vein embolism filter |
US20190117366A1 (en) * | 2017-04-28 | 2019-04-25 | Kevin T. Lie | Vascular Filter System And Method Of Deployment And Retrieval Of Vascular Filter |
CN114845665A (en) * | 2019-10-21 | 2022-08-02 | 艾迪恩特医学公司 | Absorbable blood vessel filter |
US11564786B2 (en) * | 2017-04-28 | 2023-01-31 | Kevin T. Lie | Vascular filter system and method of deployment and retrieval of a vascular filter |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107095701A (en) * | 2017-05-23 | 2017-08-29 | 上海英诺伟医疗器械有限公司 | A kind of closure basket and the plugging device with the basket |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5375612A (en) * | 1992-04-07 | 1994-12-27 | B. Braun Celsa | Possibly absorbable blood filter |
US6245103B1 (en) * | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US6972025B2 (en) * | 2003-11-18 | 2005-12-06 | Scimed Life Systems, Inc. | Intravascular filter with bioabsorbable centering element |
US20080027481A1 (en) * | 2006-07-19 | 2008-01-31 | Paul Gilson | Vascular filter |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5813961A (en) | 1981-07-18 | 1983-01-26 | Takashi Mori | Solar beam collector |
SE445884B (en) | 1982-04-30 | 1986-07-28 | Medinvent Sa | DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION |
US4817600A (en) | 1987-05-22 | 1989-04-04 | Medi-Tech, Inc. | Implantable filter |
US6171338B1 (en) | 1988-11-10 | 2001-01-09 | Biocon, Oy | Biodegradable surgical implants and devices |
US5350398A (en) * | 1991-05-13 | 1994-09-27 | Dusan Pavcnik | Self-expanding filter for percutaneous insertion |
US5443498A (en) | 1991-10-01 | 1995-08-22 | Cook Incorporated | Vascular stent and method of making and implanting a vacsular stent |
US5626605A (en) | 1991-12-30 | 1997-05-06 | Scimed Life Systems, Inc. | Thrombosis filter |
US6277084B1 (en) | 1992-03-31 | 2001-08-21 | Boston Scientific Corporation | Ultrasonic medical device |
US5317612A (en) | 1992-09-25 | 1994-05-31 | Combustion Engineering, Inc. | Use of shape memory alloys in fuel pellet holddown springs |
US5709704A (en) | 1994-11-30 | 1998-01-20 | Boston Scientific Corporation | Blood clot filtering |
CA2222673A1 (en) | 1995-05-31 | 1996-12-05 | Mitchell C. Tarczynski | Methods of increasing accumulation of essential amino acids in seeds |
US5591199A (en) | 1995-06-07 | 1997-01-07 | Porter; Christopher H. | Curable fiber composite stent and delivery system |
US5871437A (en) | 1996-12-10 | 1999-02-16 | Inflow Dynamics, Inc. | Radioactive stent for treating blood vessels to prevent restenosis |
US6007558A (en) | 1998-09-25 | 1999-12-28 | Nitinol Medical Technologies, Inc. | Removable embolus blood clot filter |
CA2360620C (en) | 1999-02-01 | 2009-09-01 | Hideki Hyodoh | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
US7018401B1 (en) | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
EP1576937B1 (en) | 1999-02-01 | 2012-10-31 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delvery of the same |
US6267776B1 (en) | 1999-05-03 | 2001-07-31 | O'connell Paul T. | Vena cava filter and method for treating pulmonary embolism |
US6146404A (en) | 1999-09-03 | 2000-11-14 | Scimed Life Systems, Inc. | Removable thrombus filter |
US6217600B1 (en) | 2000-01-26 | 2001-04-17 | Scimed Life Systems, Inc. | Thrombus filter with break-away anchor members |
WO2001062184A2 (en) | 2000-02-23 | 2001-08-30 | Boston Scientific Limited | Intravascular filtering devices and methods |
US6658558B1 (en) | 2000-03-30 | 2003-12-02 | International Business Machines Corporation | Branch prediction circuit selector with instruction context related condition type determining |
AU2001267075A1 (en) | 2000-06-13 | 2001-12-24 | Scimed Life Systems, Inc. | Disintegrating stent and method of making same |
US6582447B1 (en) | 2000-10-20 | 2003-06-24 | Angiodynamics, Inc. | Convertible blood clot filter |
US6506205B2 (en) | 2001-02-20 | 2003-01-14 | Mark Goldberg | Blood clot filtering system |
WO2008051294A2 (en) | 2006-05-02 | 2008-05-02 | C. R. Bard, Inc. | Ivc filter with translating hooks |
WO2004024032A1 (en) | 2002-09-12 | 2004-03-25 | Cook Incorporated | Retrievable filter |
AU2003285248A1 (en) | 2002-11-29 | 2004-06-23 | Vascular Interventional Technologies Inc. | Embolus blood clot filter |
US7534251B2 (en) | 2003-02-11 | 2009-05-19 | Boston Scientific Scimed, Inc. | Retrievable IVC filter |
DE10351220A1 (en) | 2003-10-28 | 2005-06-02 | Deutsche Institute für Textil- und Faserforschung Stuttgart - Stiftung des öffentlichen Rechts | Tubular implant |
CA2557583A1 (en) | 2004-01-20 | 2005-08-11 | Massachusetts General Hospital | Permanent thrombus filtering stent |
ATE503438T1 (en) | 2004-04-16 | 2011-04-15 | Cook Inc | REMOVABLE VENA CAVA FILTER TO REDUCE TRAUMA IN FOLDED STATE |
US20060025852A1 (en) | 2004-08-02 | 2006-02-02 | Armstrong Joseph R | Bioabsorbable self-expanding endolumenal devices |
US7704267B2 (en) | 2004-08-04 | 2010-04-27 | C. R. Bard, Inc. | Non-entangling vena cava filter |
US20080021497A1 (en) | 2005-01-03 | 2008-01-24 | Eric Johnson | Endoluminal filter |
US20060206138A1 (en) | 2005-03-09 | 2006-09-14 | Eidenschink Tracee E | Intravascular filter assembly |
US20070032816A1 (en) | 2005-04-04 | 2007-02-08 | B.Braun Medical | Removable Filter Head |
US20070112372A1 (en) | 2005-11-17 | 2007-05-17 | Stephen Sosnowski | Biodegradable vascular filter |
WO2007064731A2 (en) * | 2005-12-02 | 2007-06-07 | C.R. Bard, Inc. | Helical vena cava filter |
JP2009518122A (en) | 2005-12-07 | 2009-05-07 | シー・アール・バード・インコーポレイテツド | Vena cava filter with stent |
US20080107744A1 (en) | 2006-11-06 | 2008-05-08 | Jack Fa-De Chu | Injectable hollow tissue filler |
EP2263605A1 (en) | 2006-11-20 | 2010-12-22 | SeptRx, Inc. | Device and method for preventing the undesired passage of emboli from a venous blood pool to an arterial blood pool |
WO2008113857A2 (en) | 2007-03-20 | 2008-09-25 | Minvasys | Apparatus and methods for stent delivery with embolic protection |
US20080269871A1 (en) | 2007-04-27 | 2008-10-30 | Uri Eli | Implantable device with miniature rotating portion and uses thereof |
US20090163936A1 (en) | 2007-12-21 | 2009-06-25 | Chunlin Yang | Coated Tissue Engineering Scaffold |
US8236039B2 (en) | 2007-12-21 | 2012-08-07 | Abbott Laboratories | Vena cava filter having wall contacts |
US20100016881A1 (en) | 2008-07-16 | 2010-01-21 | Cook Incorporated | Biodegradable filter |
US8025675B2 (en) | 2008-08-14 | 2011-09-27 | Cook Medical Technologies Llc | Temporary filter device |
CA2736138A1 (en) * | 2008-09-05 | 2010-03-11 | Christoph Andreas Binkert | Blood filter |
US9504551B2 (en) | 2008-12-17 | 2016-11-29 | Abbott Laboratories Vascular Enterprises Limited | Apparatus for filtering a body lumen |
US9308072B2 (en) | 2009-04-15 | 2016-04-12 | Nilesh Balar | Biomedical filter |
US20120259402A1 (en) | 2009-10-30 | 2012-10-11 | Axel Grandt | Medical devices for medical device delivery systems |
US20110106234A1 (en) | 2009-10-30 | 2011-05-05 | Axel Grandt | Interluminal medical treatment devices and methods |
US20120277787A1 (en) | 2011-04-28 | 2012-11-01 | Mitchell Donn Eggers | Vascular Filter Stent |
-
2011
- 2011-02-28 US US13/036,351 patent/US20120221040A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,973 patent/US10383718B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5375612A (en) * | 1992-04-07 | 1994-12-27 | B. Braun Celsa | Possibly absorbable blood filter |
US6245103B1 (en) * | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US6972025B2 (en) * | 2003-11-18 | 2005-12-06 | Scimed Life Systems, Inc. | Intravascular filter with bioabsorbable centering element |
US20080027481A1 (en) * | 2006-07-19 | 2008-01-31 | Paul Gilson | Vascular filter |
Non-Patent Citations (1)
Title |
---|
JR Eriksen, I Gogenur, J Rosenber. "Choice of mesh for laparoscopic ventral hernia repair." Hernia (2007) 11:481-492) * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10076398B2 (en) | 2012-12-27 | 2018-09-18 | Cook Medical Technologies Llc | Biodegradable filter |
US10945824B2 (en) | 2014-03-28 | 2021-03-16 | Cook Medical Technologies Llc | Mechanism for applying high radial force in less-elastic medical devices |
US10123863B2 (en) | 2014-03-28 | 2018-11-13 | Cook Medical Technologies Llc | Mechanism for applying high radial force in less-elastic medical devices |
US10123864B2 (en) | 2014-06-30 | 2018-11-13 | Cook Medical Technologies Llc | Vascular filter and anchoring arrangement thereof |
WO2016010452A1 (en) | 2014-07-14 | 2016-01-21 | Ic "Sovremennie Tehnologii", Ltd | Multipurpose vascular implant |
US10117736B2 (en) | 2014-08-06 | 2018-11-06 | Cook Medical Technologies Llc | Low radial force filter |
US20170105830A1 (en) * | 2015-10-19 | 2017-04-20 | Cook Medical Technologies Llc | Biodegradable vascular filter |
EP3272311A1 (en) | 2016-07-21 | 2018-01-24 | Cook Medical Technologies LLC | Implantable medical device and method of manufacture |
US20190117366A1 (en) * | 2017-04-28 | 2019-04-25 | Kevin T. Lie | Vascular Filter System And Method Of Deployment And Retrieval Of Vascular Filter |
US10500034B2 (en) * | 2017-04-28 | 2019-12-10 | Kevin T. Lie | Vascular filter system and method of deployment and retrieval of vascular filter |
US11564786B2 (en) * | 2017-04-28 | 2023-01-31 | Kevin T. Lie | Vascular filter system and method of deployment and retrieval of a vascular filter |
CN107028680A (en) * | 2017-06-06 | 2017-08-11 | 贾伟 | A kind of vena cava filter |
CN109199631A (en) * | 2018-09-26 | 2019-01-15 | 李雷 | Inferior caval vein embolism filter |
CN114845665A (en) * | 2019-10-21 | 2022-08-02 | 艾迪恩特医学公司 | Absorbable blood vessel filter |
Also Published As
Publication number | Publication date |
---|---|
US20160324622A1 (en) | 2016-11-10 |
US10383718B2 (en) | 2019-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10383718B2 (en) | Absorbable vascular filter | |
US20170231743A1 (en) | Absorbable vascular filter | |
AU2016200592B2 (en) | Absorbable vascular filter | |
US20160151144A1 (en) | Vascular filter stent | |
CN102858280A (en) | Biodegradable stent having non-biodegradable end portions and mechanism for increased stent hoop strength | |
US20200113667A1 (en) | Absorbable vascular filter | |
AU2023278054A1 (en) | Bioabsorbable filament medical devices | |
CA2896028C (en) | Biodegradable intravascular filter | |
KR20220119007A (en) | Absorbent Vascular Filter | |
CN110731832B (en) | Inferior vena cava filter | |
CN112839612B (en) | Method of using self-adjusting bracket assembly and kit including same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADIENT MEDICAL, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EGGERS, MITCHELL D.;REEL/FRAME:029804/0822 Effective date: 20130110 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |